A detailed history of D. E. Shaw & Co., Inc. transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 244,681 shares of IRWD stock, worth $861,277. This represents 0.0% of its overall portfolio holdings.

Number of Shares
244,681
Holding current value
$861,277
% of portfolio
0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.93 - $7.04 $551,253 - $987,486
-140,268 Reduced 36.44%
244,681 $1.01 Million
Q2 2024

Aug 14, 2024

BUY
$5.58 - $8.61 $537,331 - $829,108
96,296 Added 33.36%
384,949 $2.51 Million
Q1 2024

May 15, 2024

BUY
$8.32 - $15.45 $496,063 - $921,175
59,623 Added 26.03%
288,653 $2.51 Million
Q4 2023

Feb 14, 2024

SELL
$8.79 - $11.51 $1.82 Million - $2.39 Million
-207,233 Reduced 47.5%
229,030 $2.62 Million
Q3 2023

Nov 14, 2023

SELL
$8.25 - $11.35 $3.98 Million - $5.48 Million
-482,735 Reduced 52.53%
436,263 $4.2 Million
Q2 2023

Aug 14, 2023

BUY
$10.1 - $11.6 $1.19 Million - $1.37 Million
118,275 Added 14.77%
918,998 $9.78 Million
Q1 2023

May 15, 2023

BUY
$10.37 - $12.56 $1.8 Million - $2.18 Million
173,337 Added 27.63%
800,723 $8.42 Million
Q4 2022

Feb 14, 2023

BUY
$9.9 - $12.43 $692,524 - $869,503
69,952 Added 12.55%
627,386 $7.77 Million
Q3 2022

Nov 14, 2022

SELL
$10.14 - $12.38 $1.97 Million - $2.4 Million
-193,995 Reduced 25.82%
557,434 $5.78 Million
Q2 2022

Aug 15, 2022

SELL
$11.05 - $12.72 $4.81 Million - $5.53 Million
-434,953 Reduced 36.66%
751,429 $8.66 Million
Q1 2022

May 16, 2022

BUY
$10.61 - $12.88 $3.21 Million - $3.89 Million
302,288 Added 34.19%
1,186,382 $14.9 Million
Q4 2021

Feb 14, 2022

SELL
$10.86 - $13.95 $4.79 Million - $6.16 Million
-441,333 Reduced 33.3%
884,094 $10.3 Million
Q3 2021

Nov 15, 2021

BUY
$11.92 - $13.92 $4.07 Million - $4.75 Million
341,189 Added 34.67%
1,325,427 $17.3 Million
Q2 2021

Aug 16, 2021

SELL
$10.16 - $13.11 $5.45 Million - $7.04 Million
-536,802 Reduced 35.29%
984,238 $12.7 Million
Q1 2021

May 17, 2021

SELL
$9.04 - $11.86 $5.59 Million - $7.33 Million
-618,187 Reduced 28.9%
1,521,040 $17 Million
Q4 2020

Feb 16, 2021

BUY
$9.05 - $12.2 $2.63 Million - $3.55 Million
290,922 Added 15.74%
2,139,227 $24.4 Million
Q3 2020

Nov 16, 2020

BUY
$8.99 - $10.74 $1.21 Million - $1.44 Million
134,118 Added 7.82%
1,848,305 $16.6 Million
Q2 2020

Aug 14, 2020

BUY
$9.14 - $11.97 $414,937 - $543,414
45,398 Added 2.72%
1,714,187 $17.7 Million
Q1 2020

May 15, 2020

BUY
$8.58 - $14.01 $1.74 Million - $2.85 Million
203,163 Added 13.86%
1,668,789 $16.8 Million
Q4 2019

Feb 14, 2020

BUY
$8.22 - $14.0 $6.55 Million - $11.2 Million
797,330 Added 119.31%
1,465,626 $19.5 Million
Q3 2019

Nov 14, 2019

BUY
$8.59 - $10.96 $265,791 - $339,124
30,942 Added 4.85%
668,296 $5.74 Million
Q2 2019

Aug 14, 2019

SELL
$9.8 - $12.89 $3.43 Million - $4.51 Million
-350,178 Reduced 35.46%
637,354 $6.97 Million
Q1 2019

May 15, 2019

BUY
$8.27 - $12.73 $2.22 Million - $3.41 Million
268,090 Added 37.26%
987,532 $13.4 Million
Q4 2018

Feb 14, 2019

BUY
$7.8 - $16.13 $3.74 Million - $7.73 Million
479,462 Added 199.79%
719,442 $7.45 Million
Q3 2018

Nov 14, 2018

BUY
$14.31 - $17.65 $1.79 Million - $2.21 Million
125,171 Added 109.03%
239,980 $4.43 Million
Q2 2018

Aug 14, 2018

SELL
$11.83 - $16.2 $680,946 - $932,488
-57,561 Reduced 33.39%
114,809 $2.2 Million
Q1 2018

May 15, 2018

SELL
$11.13 - $13.63 $1.62 Million - $1.98 Million
-145,231 Reduced 45.73%
172,370 $2.66 Million
Q4 2017

Feb 14, 2018

BUY
$12.16 - $14.58 $313,047 - $375,347
25,744 Added 8.82%
317,601 $4.76 Million
Q3 2017

Nov 14, 2017

BUY
$12.07 - $14.87 $3.52 Million - $4.34 Million
291,857
291,857 $4.6 Million

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $539M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.